InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
BioSpecialist Free
02/17/10 1:31 PM

BioSyntech Inc (BSY) RSS Feed

Followers
0
Posters
1
Posts (Today)
0
Posts (Total)
1
Created
02/17/10
Type
Free
Moderators
BST-CarGel PIII Results soon . This stock is flying under Radar .. Positive Final- Data will push this stock over 1$ !! BioSyntech (BSY.TO) Market Cap : 10,5 Mio $ Price : 0,105 $ BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel® Cartilage Repair Device June 17, 2009 http://biosyntech.com/en/investors/press.aspx?ID=111 BST-CarGel http://biosyntech.com/en/expertise/orthopedics/?BST=CarGel Insider http://canadianinsider.com/coReport/allTransactions.php?ticker=bsy Market Potential BST-CarGel® Not yet approved by Health Canada, the FDA or the European authorities BST-CarGel® is aimed at treating focalized cartilage lesions, either from trauma (sports injury or accident) or from secondary osteoarthritis (OA) degeneration. Arthroscopic view of a cartlage lesion The various surgical techniques (microfactures, mosaicplasty, autologous chondrocyte implantation) currently used all have their drawbacks including complicated or multiple surgeries, high cost and/or poor outcomes. Orthopedic surgeons perform 1.6 million of knee arthroscopic procedures each year in the USA. Cartilage lesions are found in a large number of these procedures. Additionally, a number of patients too young for arthroplasty, suffering from secondary osteoarthritic focal lesions due to previous trauma, body weight, mis-alignment of the joint or from a previous meniscal surgery, may be good candidates for BST-CarGel®. Osteoarthritis affects around 10% of the population. In the USA alone, it represents 21 million people, out of whom around 65% suffer from OA of the knee. Cartilage lesions in other joints such as the hip, ankle and the shoulder could potentially benefit from BST-CarGel®. BST-CarGel® will be more cost-effective than the overly-expensive cell-based therapies to address the challenges of the various healthcare systems around the worl
BSY Latest News
  • No Recent News Available for this company!
New Post